


**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated Statement of financial position**  
**as of 31 December 2022**


	<b>31.12.2022</b>	<b>31.12.2021</b>
	<b>BGN'000</b>	<b>BGN'000</b>
<b>Non-current assets</b>		
Property, plant and equipment	35,267	38,071
Intangible Assets and Goodwill	3,814	3,451
Trade receivables	5,276	5,276
<b>Non-current assets</b>	<b>44,357</b>	<b>46,798</b>
Inventories	13,493	11,342
Trade and other receivables	61,681	59,220
Current tax assets		40
Cash and cash equivalents	143	57
<b>Current Assets</b>	<b>75,317</b>	<b>70,659</b>
<b>Assets</b>	<b>119,674</b>	<b>117,457</b>
Issued capital	84,500	84,500
Statutory reserve	12,522	12,382
Retained earnings	4,698	1,937
<b>Equity</b>	<b>101,720</b>	<b>98,819</b>
<i>Equity Attributable to owners of the parent company</i>	<i>101,720</i>	<i>98,819</i>
<i>Non-controlling interest in equity</i>	<i>-</i>	<i>-</i>
Long term borrowings	1,281	1,717
Deferred tax liabilities	1,030	1,030
Non-current provisions for employee benefits	149	151
<b>Non-current liabilities</b>	<b>2,460</b>	<b>2,898</b>
Trade and other payables	4,812	4,721
Short term borrowings	10,523	10,771
Current tax liabilities		125
Current payables on Social Security and taxes	159	123
<b>Current liabilities</b>	<b>15,494</b>	<b>15,740</b>
<b>Liabilities</b>	<b>17,954</b>	<b>18,638</b>
<b>Equity and liabilities</b>	<b>119,674</b>	<b>117,457</b>

Date of preparation: 27.02.2023

Executive director:

  
Biser Georgiev

Prepared by:

  
Petya Moneva

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated statement of comprehensive income**  
**as 31 December 2022**


	<b>31.12.2022</b>	<b>31.12.2021</b>
	<b>BGN'000</b>	<b>BGN'000</b>
Revenue	42,959	42,431
Other income	721	124
<b>Total income</b>	<b>43,680</b>	<b>42,555</b>
Carrying amount of goods sold	(752)	(1,105)
Changes in inventories of finished products and work in progress	1,895	1,020
Materials and services	(31,867)	(30,680)
Personnel expenses	(5,770)	(5,680)
Depreciation / amortisation expenses	(3,568)	(3,877)
Other expenses	(448)	(776)
Finance income	574	507
Finance costs	(493)	(400)
<b>Total expenses</b>	<b>(40,429)</b>	<b>(40,991)</b>
<b>Profit Loss before tax</b>	<b>3,251</b>	<b>1,564</b>
Current tax expense income	(350)	(168)
<b>Profit Loss</b>	<b>2,901</b>	<b>1,396</b>
<i>Profit Loss attributable to owners of the parent company</i>	<i>2,901</i>	<i>1,396</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
<b>Other comprehensive income</b>	<b>2,901</b>	<b>1,396</b>
<i>Profit Loss attributable to owners of the parent company</i>		
<i>Profit Loss attributable to non-controlling interests</i>		
<b>Comprehensive income</b>	<b>2,901</b>	<b>1,396</b>
<i>Profit Loss attributable to owners of the parent company</i>	<i>2,901</i>	<i>1,396</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
Earnings per share / in BGN per 1 share /	0.03	0.02

Date of preparation: 27.02.2023

Executive director:

  
Biser Georgiev

Prepared by:

  
Petya Moneva

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated Cash flow statement**  
**as of 31 December 2022**

	<b>31.12.2022</b>	<b>31.12.2021</b>
	<b>BGN'000</b>	<b>BGN'000</b>
<b>Cash flows from operating activities</b>		
Receipts from sales of goods and rendering of services	33,019	33,931
Payments to suppliers for goods and services	(19,645)	(22,965)
Payments to and on behalf of employees	(5,432)	(5,518)
Income taxes paid classified as operating activities	(445)	(218)
Other cash payments from operating activities	(5,079)	(3,207)
<b>Cash flows from used in operating activities</b>	<b>2,418</b>	<b>2,023</b>
 <b>Cash flows from investing activities</b>		
Purchase of other longterm assets classified as investing activities	(1,580)	(1,573)
<b>Cash flows from used in investing activities</b>	<b>(1,580)</b>	<b>(1,573)</b>
 <b>Cash flows from financial activities</b>		
Dividends paid classified as financing activities	247	199
Proceeds from borrowings classified as financing activities	(248)	(201)
Repayments of borrowings classified as financing activities	(229)	(200)
Payments of lease liabilities classified as financing activities	(522)	(459)
		204
<b>Cash flows from used in financial activities</b>	<b>(752)</b>	<b>(457)</b>
 <b>Increase/Decrease in cash and cash equivalents</b>	<b>86</b>	<b>(7)</b>
<b>Cash and cash equivalents</b>	<b>57</b>	<b>64</b>
<b>Cash and cash equivalents</b>	<b>143</b>	<b>57</b>

Date of preparation: 27.02.2023

Executive director:

Biser Georgiev

Prepared by:

Petya Moneva

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated statement on changes in equity**  
**as of 31 December 2022**

	Property plant and equipment revaluati on	Other reserves	Retained earnings	Equity abstract	Equity Attributab le to owners of the parent company	Non- controllin g interest in equity	
	Issued capital	surplus					
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	
<b>Balance as of 01.01.2021</b>	<b>82,200</b>	<b>4,088</b>	<b>7,944</b>	<b>2,904</b>	<b>97,136</b>	<b>97,136</b>	-
Profit Loss	-	-	-	1,396	1,396	1,396	-
Other comprehensive income	-	287	-	-	287	287	-
<b>Comprehensive income</b>	-	<b>287</b>	-	<b>1,396</b>	<b>1,683</b>	<b>1,683</b>	-
Increase/Decrease through appropriation of retained earnings	2,300	-	63	(2,363)	-	-	-
<b>Total income expense</b>	<b>2,300</b>	-	<b>63</b>	<b>(2,363)</b>	-	-	-
<b>Balance as of 31.12.2021</b>	<b>84,500</b>	<b>4,375</b>	<b>8,007</b>	<b>1,937</b>	<b>98,819</b>	<b>98,819</b>	-
<b>Balance as of 01.01.2022</b>	<b>84,500</b>	<b>4,375</b>	<b>8,007</b>	<b>1,937</b>	<b>98,819</b>	<b>98,819</b>	-
Profit Loss	-	-	-	2,901	2,901	2,901	-
Other comprehensive income	-	-	-	-	-	-	-
<b>Comprehensive income</b>	-	-	-	<b>2,901</b>	<b>2,901</b>	<b>2,901</b>	-
Increase/Decrease through appropriation of retained earnings	-	-	140	(140)	-	-	-
<b>Total income expense</b>	-	-	<b>140</b>	<b>(140)</b>	-	-	-
<b>Balance as of 31.12.2022</b>	<b>84,500</b>	<b>4,375</b>	<b>8,147</b>	<b>4,698</b>	<b>101,720</b>	<b>101,720</b>	-


Date of preparation: 27.02.2023

Executive director:



Biser Georgiev

Prepared by:



Petya Moneva